50 years of hurdles and hope in anxiolytic drug discovery

Nature Reviews Drug Discovery

Volumn 12, Issue 9, 2013, Pages 667-687

  Griebel, Guy ^a   Holmes, Andrew ^b  

^a SANOFI   (France)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; DIAZEPAM; ENDOCANNABINOID; GLUTAMIC ACID; IMIPRAMINE; NEUROPEPTIDE; NORADRENALIN UPTAKE INHIBITOR; PREGABALIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TALAGLUMETAD; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; DSM-IV; GENERALIZED ANXIETY DISORDER; HUMAN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SOCIAL PHOBIA;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84883336698     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4075     Document Type: Review

References (286)

1. Kessler, R. C. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J. Clin. Psychiatry 68 (Suppl. 2), 10-19 (2007).
2. Wittchen, H. U. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 655-679 (2011).
3. Kessler, R. C. et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch. Gen. Psychiatry 68, 90-100 (2011).
4. Kessler, R. C. et al. The WHO World Mental Health (WMH) Surveys. Psychiatrie 6, 5-9 (2009).
5. Ormel, J. et al. Disability and treatment of specific mental and physical disorders across the world. Br. J. Psychiatry 192, 368-375 (2008).
6. Kupfer, D. J. & Regier, D. A. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am. J. Psychiatry 168, 672-674 (2011).
7. Craddock, N. & Owen, M. J. The Kraepelinian dichotomy-going, going... but still not gone. Br. J. Psychiatry 196, 92-95 (2010).
8. Leucht, S., Heres, S. & Davis, J. M. Considerations about the efficacy of psychopharmacological drugs. Nervenartz 82, 1425-1430 (2011).
9. Caspi, A., Hariri, A. R., Holmes, A., Uher, R. & Moffitt, T. E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 167, 509-527 (2010).
10. Owen, D. R., Rupprecht, R. & Nutt, D. J. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety J. Psychopharmacol. 27, 119-122 (2013).
11. Nothdurfter, C., Rupprecht, R. & Rammes, G. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO). Curr. Top. Med. Chem. 12, 360-370 (2012).
12. Belzung, C. & Lemoine, M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. Mood Anxiety Disord. 1, 9-14 (2011).
13. Haller, J., Aliczki, M. & Gyimesine, P. K. Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci. Biobehav. Rev. http://dx.doi.org/10.1016/j.neubiorev.2012.09.001 (2012).
14. Cryan, J. F. & Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Rev. Drug Discov. 4, 775-790 (2005).
15. McKinney, W. T. Jr & Bunney, W. E. Jr. Animal model of depression. I. Review of evidence: implications for research. Arch. Gen. Psychiatry 21, 240-248 (1969).
16. Hall, C. S. Emotional behavior in the rat. I: defecation and urination as measures of individual differences in emotionality. J. Comp. Psychol. 18, 385-403 (1934).
17. Handley, S. L. & Mithani, S. Effects of-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedeberg Arch. Pharmacol. 327, 1-5 (1984).
18. Crawley, J. N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15, 695-699 (1981).
19. Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92, 180-185 (1987).
20. Vogel, J. R., Beer, B. & Clody, D. E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21, 1-7 (1971).
21. Geller, I., Kulak, J. T. & Seifter, J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3, 374-385 (1962).
22. Griebel, G. & Beesk, S. in Mood and Anxiety Related Phenotypes in Mice (ed. Gould, T. D.) 97-106 (Springer, 2011).
23. Blanchard, D. C., Griebel, G. & Blanchard, R. J. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 463, 97-116 (2003).
24. Rodgers, R. J., Cao, B. J., Dalvi, A. & Holmes, A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30, 289-304 (1997).
25. Steckler, T. & Risbrough, V. Pharmacological treatment of PTSD-established and new approaches. Neuropharmacology 62, 617-627 (2012).
26. Mozhui, K. et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J. Neurosci. 30, 5357-5367 (2010).
27. Belzung, C., El Hage, W., Moindrot, N. & Griebel, G. Behavioral and neurochemical changes following predatory stress in mice. Neuropharmacology 41, 400-408 (2001).
28. Muigg, P. et al. Differential stress-induced neuronal activation patterns in mouse lines selectively bred for high, normal or low anxiety. PLoS ONE 4, e5346 (2009).
29. Holmes, A. & Singewald, N. Individual differences in recovery from traumatic fear. Trends Neurosci. 36, 23-31 (2013).
30. Holmes, A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293-1314 (2008).
31. Holmes, A. J. et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J. Neurosci. 32, 18087-18100 (2012).
32. Donaldson, Z. R., Nautiyal, K. M., Ahmari, S. E. & Hen, R. Genetic approaches for understanding the role of serotonin receptors in mood and behavior. Curr. Opin. Neurobiol. 23, 399-406 (2013).
33. Holmes, A. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci. Biobehav. Rev. 25, 261-273 (2001).
34. Tye, K. M. & Deisseroth, K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Rev. Neurosci. 13, 251-266 (2012).
35. Tye, K. M. et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471, 358-362 (2011).
36. Johansen, J. P. et al. Optical activation of lateral amygdala pyramidal cells instructs associative fear learning. Proc. Natl Acad. Sci. USA 107, 12692-12697 (2010).
37. Fisher, P. M. & Hariri, A. R. Linking variability in brain chemistry and circuit function through multimodal human neuroimaging. Genes Brain Behav. 11, 633-642 (2012).
38. Holmes, A. & Quirk, G. J. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders-the case of yohimbine. Trends Pharmacol. Sci. 31, 2-7 (2010).
39. Myers, K. M. & Davis, M. Mechanisms of fear extinction. Mol. Psychiatry 12, 120-150 (2007).
40. Richardson, R., Ledgerwood, L. & Cranney, J. Facilitation of fear extinction by d-cycloserine: theoretical and clinical implications. Learn. Mem. 11, 510-516 (2004).
41. Baldwin, D. S. & Garner, M. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 395-411 (Elsevier, 2008).
42. Baldwin, D. S., Ajel, K. I. & Garner, M. Pharmacological treatment of generalized anxiety disorder. Curr. Top. Behav. Neurosci. 2, 453-467 (2010).
43. Hoffman, E. J. & Mathew, S. J. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt. Sinai J. Med. 75, 248-262 (2008).
44. Rudolph, U. & Knoflach, F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Rev. Drug Discov. 10, 685-697 (2011).
45. VanSteveninck, A. L. et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol. 41, 565-573 (1996).
46. Guldner, J. et al. Bretazenil modulates sleep EEG and nocturnal hormone secretion in normal men. Psychopharmacology 122, 115-121 (1995).
47. de Haas, S. L. et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J. Psychopharmacol. 23, 625-632 (2008).
48. Surhone, L. M., Timpledon, M. T. & Marseken, S. F. Ocinaplon (VDM Publishing House, 2010).
49. de Haas, S. L. et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA 2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J. Psychopharmacol. 21, 374-383 (2007).
50. Rupprecht, R. et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325, 490-493 (2009).
51. Owen, D. R. et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse 65, 257-259 (2011).
52. Griebel, G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65, 319-395 (1995).
53. Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996).
54. Hariri, A. R. & Holmes, A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn. Sci. 10, 182-191 (2006).
55. Belzung, C. & Griebel, G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125, 141-149 (2001).
56. Jacobson, L. H. & Cryan, J. F. Genetic approaches to modeling anxiety in animals. Curr. Top. Behav. Neurosci. 2, 161-201 (2010).
57. Goldberg, H. L. & Finnerty, R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 136, 1184-1187 (1979).
58. Rickels, K. et al. Buspirone and diazepam in anxiety: a controlled study. J. Clin. Psychiatry 43, 81-86 (1982).
59. Akimova, E., Lanzenberger, R. & Kasper, S. The serotonin-1A receptor in anxiety disorders. Biol. Psychiatry 66, 627-635 (2009).
60. Goodfellow, N. M., Benekareddy, M., Vaidya, V. A. & Lambe, E. K. Layer II/III of the prefrontal cortex: Inhibition by the serotonin 5-HT1A receptor in development and stress. J. Neurosci. 29, 10094-10103 (2009).
61. Zhang, J. et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J. Neurosci. 30, 2433-2441 (2010).
62. Chessick, C. A. et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. 2006, CD006115 (2006).
63. Gammans, R. E., Mayol, R. F. & LaBudde, J. A. Metabolism and disposition of buspirone. Am. J. Med. 80, 41-51 (1986).
64. Nutt, D. J. & Ballenger, J. C. Anxiety Disorders (Blackwell Science, 2003).
65. Kent, J. M., Coplan, J. D. & Gorman, J. M. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry 44, 812-824 (1998).
66. Nutt, D. J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10, 49-56 (2005).
67. Gartside, S. E., Umbers, V., Hajos, M. & Sharp, T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115, 1064-1070 (1995).
68. Vaswani, M., Linda, F. K. & Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 85-102 (2003).
69. Crabbe, J. C., Wahlsten, D. & Dudek, B. C. Genetics of mouse behavior: interactions with laboratory environment. Science 284, 1670-1672 (1999).
70. Handley, S. L. & McBlane, J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods 29, 129-138 (1993).
71. Sanger, D. J. Effects of buspirone and related compounds on suppressed operant responding in rats. J. Pharmacol. Exp. Ther. 254, 420-426 (1990).
72. Maier, S. F. & Watkins, L. R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev. 29, 829-841 (2005).
73. Stein, D. J., Ahokas, A. A., & de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28, 561-566 (2008).
74. Belzung, C., Yalcin, I., Griebel, G., Surget, A. & Leman, S. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol. Disord. Drug Targets 5, 135-145 (2006).
75. Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T. & Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 24, 580-588 (2003).
76. van den Pol, A. N. Neuropeptide transmission in brain circuits. Neuron 76, 98-115 (2012).
77. Steckler, T. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead Curr. Top. Behav. Neurosci. 2, 415-428 (2010).
78. Griebel, G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders Pharmacol. Ther. 82, 1-61 (1999).
79. Van der Haegen, J. J., Signeau, J. C. & Gepts, W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257, 604-605 (1975).
80. Moran, T. H., Robinson, P. H., Goldrich, M. S. & McHugh, P. R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362, 175-179 (1986).
81. Griebel, G. & Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning Nature Rev. Drug Discov. 11, 462-478 (2012).
82. Vale, W. W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and-endorphin. Science 213, 1394-1397 (1981).
83. Chalmers, D. T., Lovenberg, T. W. & De Souza, E. B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340-6350 (1995).
84. Turiault, M., Cohen, C. & Griebel, G. in Encyclopedia of Psychopharmacology (ed. Stolerman, I. P.) 1301-1303 (Springer-Verlag, 2010).
85. Regoli, D., Boudon, A. & Fauchere, J. L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551-599 (1994).
86. Griebel, G. & Beeske, S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases Pharmacol. Ther. 133, 116-123 (2012).
87. Brothers, S. P. & Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med. 2, 429-439 (2010).
88. Civelli, O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl. Cell Differ. 46, 1-25 (2008).
89. Lang, R., Gundlach, A. L. & Kofler, B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 115, 177-207 (2007).
90. Shimazaki, T., Yoshimizu, T. & Chaki, S. Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20, 801-811 (2006).
91. Chung, S. et al. The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS ONE 6, e19286 (2011).
92. Xu, Y. L. et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43, 487-497 (2004).
93. Sah, R. & Geracioti, T. D. Neuropeptide Y and posttraumatic stress disorder. Mol. Psychiatry 18, 646-655 (2013).
94. Krystal, J. H. et al. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24, 669-693 (2010).
95. Dunayevich, E. et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33, 1603-1610 (2008).
96. Bergink, V. & Westenberg, H. G. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int. Clin. Psychopharmacol. 20, 291-293 (2005).
97. Sanacora, G., Zarate, C. A., Krystal, J. H. & Manji, H. K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev. Drug Discov. 7, 426-437 (2008).
98. Ressler, K. J. et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 61, 1136-1144 (2004).
99. Norberg, M. M., Krystal, J. H. & Tolin, D. F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 63, 1118-1126 (2008).
100. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932-1936 (1990).
101. Gunduz-Cinar, O. et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18, 813-823 (2013).
102. Neumeister, A. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2013.61 (2013).
103. Griebel, G., Stemmelin, J. & Scatton, B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57, 261-267 (2005).
104. Jacob, W. et al. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav. 8, 685-698 (2009).
105. Haller, J., Varga, B., Ledent, C. & Freund, T. F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15, 299-304 (2004).
106. Moreira, F. A. & Wotjak, C. T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2, 429-450 (2010).
107. Metna-Laurent, M. et al. Bimodal control of fear-coping strategies by CB1 cannabinoid receptors. J. Neurosci. 32, 7109-7118 (2012).
108. Topol, E. J. et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517-523 (2010).
109. Hill, M. N. et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol. Psychiatry http://dx.doi.org/10.1038/mp.2012.90 (2012).
110. Bortolato, M. & Piomelli, D. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D.) 303-324 (Elsevier, 2008).
111. Micale, V. et al. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138, 18-37 (2013).
112. Collins, P. Y. et al. Grand challenges in global mental health. Nature 475, 27-30 (2011).
113. Rodgers, R. J. Animal models of 'anxiety': where next Behav. Pharmacol. 8, 477-496 (1997).
114. Crestani, F., Martin, J. R., Mohler, H. & Rudolph, U. Resolving differences in GABAA receptor mutant mouse studies. Nature Neurosci. 3, 1059 (2000).
115. Kessler, R. C. et al. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch. Gen. Psychiatry 69, 381-389 (2012).
116. Blanchard, D. C., Griebel, G. & Blanchard, R. J. Gender bias in the preclinical psychopharmacology of anxiety: male models for (predominantly) female disorders. J. Psychopharmacol. 9, 79-82 (1995).
117. Palanza, P. Animal models of anxiety and depression: how are females different Neurosci. Biobehav. Rev. 25, 219-233 (2001).
118. Soldin, O. P. & Mattison, D. R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48, 143-157 (2009).
119. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682-690 (2008).
120. Youdim, M. B. & Buccafusco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27-35 (2005).
121. Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215-220 (2012).
122. Bottegoni, G., Favia, A. D., Recanatini, M. & Cavalli, A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today 17, 23-34 (2012).
123. Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M. & Deisseroth, K. Optogenetics in neural systems. Neuron 71, 9-34 (2011).
124. Covington, H. E. et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30, 16082-16090 (2010).
125. American Psychiatric Association Taskforce on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (American Psychiatric Association, 2000).
126. Nutt, D. J., Garcia de Miguel, B. & Davies, S. J. C. in Handbook of Anxiety and Fear (eds Blanchard, R. J., Blanchard, D. C., Griebel, G. & Nutt, D. J.) 365-393 (Academic Press, 2008).
127. Reinhold, J. A., Mandos, L. A., Rickels, K. & Lohoff, F. W. Pharmacological treatment of generalized anxiety disorder. Expert. Opin. Pharmacother. 12, 2457-2467 (2011).
128. Kessler, R. C. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593-602 (2005).
129. Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627 (2005).
130. Jeffreys, M., Capehart, B. & Friedman, M. J. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J. Rehabil. Res. Dev. 49, 703-715 (2012).
131. Stein, M., Steckler, T., Lightfoot, J. D., Hay, E. & Goddard, A. W. Pharmacologic treatment of panic disorder. Curr. Top. Behav. Neurosci. 2, 469-485 (2010).
132. Kessler, R. C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8-19 (1994).
133. Ganasen, K. A. & Stein, D. J. Pharmacotherapy of social anxiety disorder. Curr. Top. Behav. Neurosci. 2, 487-503 (2010).
134. Abudy, A., Juven-Wetzler, A. & Zohar, J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 25, 585-596 (2011).
135. Varty, G. B., Morgan, C. A., Cohen-Williams, M. E., Coffin, V. L. & Carey, G. J. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27, 357-370 (2002).
136. Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J. & Dourish, C. T. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 116, 56-64 (1994).
137. Rex, A., Marsden, C. A. & Fink, H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology 110, 490-496 (1993).
138. Misslin, R., Belzung, C. & Vogel, E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8, 119-132 (1989).
139. de Angelis, L. & File, S. E. Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology 64, 127-129 (1979).
140. File, S. E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods 2, 219-238 (1980).
141. Thiebot, M. H., Dangoumau, L., Richard, G. & Puech, A. J. Safety signal withdrawal: a behavioural paradigm sensitive to both " anxiolytic" and "anxiogenic" drugs under identical experimental conditions. Psychopharmacology 103, 415-424 (1991).
142. Winslow, J. T. & Insel, T. R. The infant rat separation paradigm: a novel test for novel anxiolytics. Trends Pharmacol. Sci. 12, 402-404 (1991).
143. Vinkers, C. H. et al. Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur. J. Pharmacol. 585, 407-425 (2008).
144. Boissier, J. R., Simon, P. & Aron, C. A new method for the rapid screening of minor tranquillisers in mice. Eur. J. Pharmacol. 4, 145-151 (1968).
145. Njung'e, K. & Handley, S. L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 38, 63-67 (1991).
146. Treit, D., Pinel, J. P. & Fibiger, H. C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol. Biochem. Behav. 15, 619-626 (1981).
147. Davis, M. Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav. Neurosci. 100, 814-824 (1986).
148. Geyer, M. A., Petersen, L. R. & Rose, G. J. Effects of serotonergic lesions on investigatory responding by rats in a holeboard. Behav. Neural. Biol. 30, 160-177 (1980).
149. Bodnoff, S. R., Suranyi Cadotte, B., Aitken, D. H., Quirion, R. & Meaney, M. J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 95, 298-302 (1988).
150. Viana, M. B., Tomaz, C. & Graeff, F. G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49, 549-554 (1994).
151. Espana, J. et al. Intraneuronal-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol. Psychiatry 67, 513-521 (2010).
152. Richardson-Jones, J. W. et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 31, 6008-6018 (2011).
153. Gleason, G. et al. The serotonin1A receptor gene as a genetic and prenatal maternal environmental factor in anxiety. Proc. Natl Acad. Sci. USA 107, 7592-7597 (2010).
154. Tsetsenis, T., Ma, X. H., Lo, I. L., Beck, S. G. & Gross, C. Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nature Neurosci. 10, 896-902 (2007).
155. Klemenhagen, K. C., Gordon, J. A., David, D. J., Hen, R. & Gross, C. T. Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology 31, 101-111 (2005).
156. Li, Q. et al. Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: application of recombinant adenovirus containing 5-HT1A sequences. J. Neurosci. 24, 10868-10877 (2004).
157. Bailey, S. J. & Toth, M. Variability in the benzodiazepine response of serotonin 5-HT1A receptor null mice displaying anxiety-like phenotype: evidence for genetic modifiers in the 5-HT-mediated regulation of GABAA receptors. J. Neurosci. 24, 6343-6351 (2004).
158. Pattij, T. et al. Autonomic changes associated with enhanced anxiety in 5-HT1A receptor knockout mice. Neuropsychopharmacology 27, 380-390 (2002).
159. Gross, C. et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416, 396-400 (2002).
160. Sibille, E., Pavlides, C., Benke, D. & Toth, M. Genetic inactivation of the serotonin1A receptor in mice results in downregulation of major GABAA receptor subunits, reduction of GABAA receptor binding, and benzodiazepine- resistant anxiety. J. Neurosci. 20, 2758-2765 (2000).
161. Ramboz, S. et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA 95, 14476-14481 (1998).
162. Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T. & Toth, M. Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95, 10734-10739 (1998).
163. Heisler, L. K. et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15049-15054 (1998).
164. Guilloux, J. P. et al. Characterization of 5-HT1A/1B-/-mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology 61, 478-488 (2011).
165. Mombereau, C., Kawahara, Y., Gundersen, B. B., Nishikura, K. & Blendy, J. A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant-and anxiety-like behaviors. Neuropharmacology 59, 468-473 (2010).
166. Bhatnagar, S. et al. Changes in anxiety-related behaviors and hypothalamic-pituitary-adrenal activity in mice lacking the 5-HT-3A receptor. Physiol. Behav. 81, 545-555 (2004).
167. Bhatnagar, S., Nowak, N., Babich, L. & Bok, L. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav. Brain Res. 153, 527-535 (2004).
168. Narayanan, V. et al. Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS ONE 6, e22600 (2011).
169. Line, S. J. et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur. Neuropsychopharmacol. 21, 108-116 (2011).
170. Heiming, R. S. et al. Living in a dangerous world: the shaping of behavioral profile by early environment and 5-HTT genotype. Front. Behav. Neurosci. 3, 26 (2009).
171. Wellman, C. L. et al. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27, 684-691 (2007).
172. Carroll, J. C. et al. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav. Genet. 37, 214-222 (2007).
173. Ansorge, M. S., Zhou, M., Lira, A., Hen, R. & Gingrich, J. A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879-881 (2004).
174. Lira, A. et al. Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960-971 (2003).
175. Holmes, A., Yang, R. J., Lesch, K. P., Crawley, J. N. & Murphy, D. L. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28, 2077-2088 (2003).
176. Hasegawa, S. et al. Transgenic up-regulation of-CaMKII in forebrain leads to increased anxiety-like behaviors and aggression. Mol. Brain 2, 6 (2009).
177. Ledent, C. et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388, 674-678 (1997).
178. Lhdesmaki, J. et al. Behavioral and neurochemical characterization of 2a-adrenergic receptor knockout mice. Neuroscience 113, 289-299 (2002).
179. Schramm, N. L., McDonald, M. P. & Limbird, L. E. The 2a-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21, 4875-4882 (2001).
180. Okuyama, S. et al. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res. 821, 150-159 (1999).
181. Ichiki, T. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377, 748-750 (1995).
182. Raber, J. Role of apolipoprotein E in anxiety. Neural Plast. 2007, 91236 (2007).
183. Dubreucq, S. et al. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37, 1885-1900 (2012).
184. Kamprath, K. et al. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav. 8, 203-211 (2009).
185. Bura, S. A., Burokas, A., Martin-Garcia, E. & Maldonado, R. Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice. Eur. Neuropsychopharmacol. 20, 369-378 (2010).
186. Tourino, C., Ledent, C., Maldonado, R. & Valverde, O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol. Psychiatry 63, 1030-1038 (2008).
187. Kamprath, K. et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 26, 6677-6686 (2006).
188. Haller, J., Varga, B., Ledent, C., Barna, I. & Freund, T. F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 19, 1906-1912 (2004).
189. Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534 (2002).
190. Haller, J., Bakos, N., Szirmay, M., Ledent, C. & Freund, T. F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16, 1395-1398 (2002).
191. Maccarrone, M. et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15, 1178-1186 (2002).
192. Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159, 379-387 (2002).
193. Gogos, J. A. et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl Acad. Sci. USA 95, 9991-9996 (1998).
194. Yamamoto, Y. et al. Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Brain Res. Bull. 53, 789-792 (2000).
195. Kobayashi, S., Ohta, M., Miyasaka, K. & Funakoshi, A. Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)A receptor gene knockout rats. Neurosci. Lett. 214, 61-64 (1996).
196. Abramov, U. et al. Different housing conditions alter the behavioural phenotype of CCK2 receptor-deficient mice. Behav. Brain Res. 193, 108-116 (2008).
197. Miyasaka, K. et al. Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci. Lett. 335, 115-118 (2002).
198. Vasar, E. et al. CCKB receptor knockout mice: gender related behavioural differences. Eur. Neuropsychopharmacol. 10 (Suppl. 2), 69 (2000).
199. Chen, Q., Nakajima, A., Meacham, C. & Tang, Y. P. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc. Natl Acad. Sci. USA 103, 3881-3886 (2006).
200. Kolber, B. J. et al. Transient early-life forebrain corticotropin- releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J. Neurosci. 30, 2571-2581 (2010).
201. van Gaalen, M. M., Stenzel-Poore, M. P., Holsboer, F. & Steckler, T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15, 2007-2015 (2002).
202. Heinrichs, S. C. et al. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22, 215-224 (1997).
203. Stenzel-Poore, M. P., Duncan, J. E., Rittenberg, M. B., Bakke, A. C. & Heinrichs, S. C. CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann. NY Acad. Sci. 780, 36-48 (1996).
204. Stenzel-Poore, M. P., Heinrichs, S. C., Rivest, S., Koob, G. F. & Vale, W. W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14, 2579-2584 (1994).
205. Ramesh, T. M., Karolyi, I. J., Nakajima, M., Camper, S. A. & Seasholtz, A. F. Altered physiological and behavioral responses in CRH-binding protein deficient mice. Abstr. Soc. Neurosci. 24, 505 (1998).
206. Karolyi, I. J. et al. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc. Natl Acad. Sci. USA 96, 11595-11600 (1999).
207. Refojo, D. et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333, 1903-1907 (2011).
208. Kishimoto, T. et al. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genet. 24, 415-419 (2000).
209. Coste, S. C. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genet. 24, 403-409 (2000).
210. Bale, T. L. et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. 24, 410-414 (2000).
211. Umehara, F. et al. Elevated anxiety-like and depressive behavior in Desert hedgehog knockout male mice. Behav. Brain Res. 174, 167-173 (2006).
212. Dulawa, S. C., Grandy, D. K., Low, M. J., Paulus, M. P. & Geyer, M. A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J. Neurosci. 19, 9550-9556 (1999).
213. Ogawa, S., Lubahn, D. B., Korach, K. S. & Pfaff, D. W. Behavioral effects of estrogen receptor gene disruption in male mice. Proc. Natl Acad. Sci. USA 94, 1476-1481 (1997).
214. Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva-Paylor, L. A. & Paylor, R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420-430 (2005).
215. Miyakawa, T., Yagi, T., Watanabe, S. & Niki, H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Brain Res. Mol. Brain Res. 27, 179-182 (1994).
216. Sonner, J. M. et al. 1 subunit-containing GABA type A receptors in forebrain contribute to the effect of inhaled anesthetics on conditioned fear. Mol. Pharmacol. 68, 61-68 (2005).
217. Dixon, C. I., Rosahl, T. W. & Stephens, D. N. Targeted deletion of the GABRA2 gene encoding 2-subunits of GABAA receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates. Pharmacol. Biochem. Behav. 90, 1-8 (2008).
218. Hashemi, E., Sahbaie, P., Davies, M. F., Clark, J. D. & Delorey, T. M. Gabrb3 gene deficient mice exhibit increased risk assessment behavior, hypotonia and expansion of the plexus of locus coeruleus dendrites. Brain Res. 1129, 191-199 (2007).
219. Liljelund, P., Ferguson, C., Homanics, G. & Olsen, R. W. Long-term effects of diazepam treatment of epileptic GABAA receptor 3 subunit knockout mouse in early life. Epilepsy Res. 66, 99-115 (2005).
220. Earnheart, J. C. et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J. Neurosci. 27, 3845-3854 (2007).
221. Homanics, G. E. et al. Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the 2 subunit of the-aminobutyrate type A receptor. Neuropharmacology 38, 253-265 (1999).
222. Crestani, F. et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nature Neurosci. 2, 833-839 (1999).
223. Chandra, D., Korpi, E. R., Miralles, C. P., De Blas, A. L. & Homanics, G. E. GABAA receptor 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci. 6, 30 (2005).
224. Mombereau, C. et al. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 16, 307-310 (2005).
225. Mombereau, C., Kaupmann, K., van der Putten, H. & Cryan, J. F. Altered response to benzodiazepine anxiolytics in mice lacking GABAB(1) receptors. Eur. J. Pharmacol. 497, 119-120 (2004).
226. Mombereau, C. et al. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety-and antidepressant-like behavior. Neuropsychopharmacology 29, 1050-1062 (2004).
227. Sangha, S. et al. Deficiency of the 65 kDa isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. J. Neurosci. 29, 15713-15720 (2009).
228. Bergado-Acosta, J. R. et al. Critical role of the 65-kDa isoform of glutamic acid decarboxylase in consolidation and generalization of Pavlovian fear memory. Learn. Mem. 15, 163-171 (2008).
229. Stork, O., Yamanaka, H., Stork, S., Kume, N. & Obata, K. Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav. 2, 65-70 (2003).
230. Stork, O. et al. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res. 865, 45-58 (2000).
231. Kash, S. F., Tecott, L. H., Hodge, C. & Baekkeskov, S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 96, 1698-1703 (1999).
232. Chiu, C. S. et al. GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J. Neurosci. 25, 3234-3245 (2005).
233. Holmes, A. et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 28, 1031-1044 (2003).
234. Wei, Q. et al. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl Acad. Sci. USA 101, 11851-11856 (2004).
235. Labrie, V. & Roder, J. C. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 34, 351-372 (2009).
236. Delawary, M. et al. NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala. Mol. Brain 3, 37 (2010).
237. Davis, M. J., Haley, T., Duvoisin, R. M. & Raber, J. Measures of anxiety, sensorimotor function, and memory in male and female mGluR4-/-mice. Behav. Brain Res. 229, 21-28 (2012).
238. Wu, L. J. et al. Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS ONE 2, e167 (2007).
239. Linden, A. M. et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43, 251-259 (2002).
240. Duvoisin, R. M., Villasana, L., Davis, M. J., Winder, D. G. & Raber, J. Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav. Brain Res. 221, 50-54 (2011).
241. Robbins, M. J. et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 1152, 215-227 (2007).
242. Sparta, D. R., Fee, J. R., Knapp, D. J., Breese, G. R. & Thiele, T. E. Elevated anxiety-like behavior following ethanol exposure in mutant mice lacking neuropeptide Y (NPY). Drug Alcohol Depend. 90, 297-300 (2007).
243. Duvoisin, R. M. et al. Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8. Eur. J. Neurosci. 22, 425-436 (2005).
244. Acevedo, S. F., Pfankuch, T., Ohtsu, H. & Raber, J. Anxiety and cognition in female histidine decarboxylase knockout (Hdc-/-) mice. Behav. Brain Res. 168, 92-99 (2006).
245. Kustova, Y., Sei, Y., Morse, H. C. Jr. & Basile, A. S. The influence of a targeted deletion of the IFN gene on emotional behaviors. Brain Behav. Immun. 12, 308-324 (1998).
246. Armario, A., Hernandez, J., Bluethmann, H. & Hidalgo, J. IL-6 deficiency leads to increased emotionality in mice: evidence in transgenic mice carrying a null mutation for IL-6. J. Neuroimmunol. 92, 160-169 (1998).
247. Walther, T. et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. 273, 11867-11873 (1998).
248. Nakamura, E. et al. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 3, 811-822 (1998).
249. Stork, O. et al. Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. J. Neurobiol. 40, 343-355 (1999).
250. Ross, S. A. et al. Phenotypic characterization of an 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 20, 6431-6441 (2000).
251. Ouagazzal, A. M., Moreau, J. L., Pauly-Evers, M. & Jenck, Z. F. Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav. Brain Res. 144, 111-117 (2003).
252. Frisch, C. et al. Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum. J. Neurosci. 20, 6694-6700 (2000).
253. Köster, A. et al. Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl Acad. Sci. USA 96, 10444-10449 (1999).
254. Gavioli, E. C. et al. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28, 1229-1239 (2007).
255. Painsipp, E., Herzog, H., Sperk, G. & Holzer, P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br. J. Pharmacol. 163, 1302-1314 (2011).
256. Bannon, A. W. et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868, 79-87 (2000).
257. Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C. & Schwartz, M. W. Life without neuropeptide Y. Recent Prog. Horm. Res. 53, 163-199 (1998).
258. Inui, A. et al. Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc. Assoc. Am. Physicians 110, 171-182 (1998).
259. Karl, T., Burne, T. H. & Herzog, H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav. Brain Res. 167, 87-93 (2006).
260. Konig, M. et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383, 535-538 (1996).
261. Osada, T. et al. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. J. Neurosci. 19, 6068-6078 (1999).
262. Zhao, L. et al. Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior. Mol. Endocrinol. 22, 1403-1415 (2008).
263. Chrast, R. et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Hum. Mol. Genet. 9, 1853-1864 (2000).
264. Sun, Y., Zupan, B., Raaka, B. M., Toth, M. & Gershengorn, M. C. TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology 34, 1601-1608 (2009).
265. Sekiyama, K. et al. Abnormalities in aggression and anxiety in transgenic mice overexpressing activin E. Biochem. Biophys. Res. Commun. 385, 319-323 (2009).
266. Dierssen, M. et al. Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol. Dis. 24, 403-418 (2006).
267. Fiore, M. et al. Exploratory and displacement behavior in transgenic mice expressing high levels of brain TNF-. Physiol. Behav. 63, 571-576 (1998).
268. Ehninger, D. & Silva, A. J. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav. Genet. 41, 357-363 (2011).
269. Bielsky, I. F., Hu, S. B., Ren, X., Terwilliger, E. F. & Young, L. J. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 47, 503-513 (2005).
270. Crawley, J. N. & Davis, L. G. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res. Bull. 8, 609-612 (1982).
271. Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107-124 (1997).
272. Griebel, G., Belzung, C., Misslin, R. & Vogel, E. The free-exploratory paradigm: an effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs. Behav. Pharmacol. 4, 637-644 (1993).
273. Pobbe, R. L. et al. General and social anxiety in the BTBR T+ tf/J mouse strain. Behav. Brain Res. 216, 446-451 (2011).
274. Kantor, S., Anheuer, Z. E. & Bagdy, G. High social anxiety and low aggression in Fawn-Hooded rats. Physiol. Behav. 71, 551-557 (2000).
275. Kromer, S. A. et al. Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J. Neurosci. 25, 4375-4384 (2005).
276. Salome, N. et al. Reliability of high and low anxiety-related behaviour: influence of laboratory environment and multifactorial analysis. Behav. Brain Res. 136, 227-237 (2002).
277. Landgraf, R. et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci. Biobehav. Rev. 31, 89-102 (2007).
278. Commissaris, R. L., Harrington, G. M. & Altman, H. J. Benzodiazepine anti-conflict effects in Maudsley reactive (MR/Har) and non-reactive (MNRA/Har) rats. Psychopharmacology 100, 287-292 (1990).
279. Commissaris, R. L., McCloskey, T. C., Harrington, G. M. & Altman, H. J. MR/Har and MNRA/Har Maudsley rat strains: differential response to chlordiazepoxide in a conflict task. Pharmacol. Biochem. Behav. 32, 801-805 (1989).
280. Blizard, D. A. & Adams, N. The Maudsley reactive and nonreactive strains: a new perspective. Behav. Genet. 32, 277-299 (2002).
281. Lopez-Aumatell, R. et al. Unlearned anxiety predicts learned fear: a comparison among heterogeneous rats and the Roman rat strains. Behav. Brain Res. 202, 92-101 (2009).
282. Yilmazer-Hanke, D. M., Faber-Zuschratter, H., Linke, R. & Schwegler, H. Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high-and low-avoidance rats. Eur. J. Neurosci. 15, 1206-1218 (2002).
283. Steimer, T., Driscoll, P. & Schulz, P. E. Brain metabolism of progesterone, coping behaviour and emotional reactivity in male rats from two psychogenetically selected lines. J. Neuroendocrinol. 9, 169-175 (1997).
284. McAuley, J. D. et al. Wistar-Kyoto rats as an animal model of anxiety vulnerability: support for a hypervigilance hypothesis. Behav. Brain Res. 204, 162-168 (2009).
285. Par, W. P., Kluczynski, S. M. & Tejani-Butt, S. M. Strain differences in the open field test and the Porsolt forced swim test following antidepressant treatment. Abstr. Soc. Neurosci. 25, 1583 (1999).
286. Davis, M., Walker, D. L., Miles, L. & Grillon, C. Phasic versus sustained fear in rats and humans: role of the extended amygdala in fear versus anxiety. Neuropsychopharmacology 35, 105-135 (2010).